Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances?
Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances? Kalkine Media
Covered in this story
Analyst targets on Amgen
- Cantor Fitzgerald: $403 → $400 by Oct 2027 · Neutral via Investing.com
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from Kalkine Media's public RSS feed. The full reporting belongs to Kalkine Media — please read it on their site.